Skip to main content

Benign Prostatic Hyperplasia



  1. 1.

    Define the pathophysiology, incidence, presenting symptoms, and risk factors of BPH.

  2. 2.

    Discuss assessment techniques associated with BPH.

  3. 3.

    Explain treatment options including pharmacologic, watchful waiting, and surgical.

  4. 4.

    Discuss complications and side effects of treatment options.


  • Erectile Dysfunction
  • Benign Prostatic Hyperplasia
  • Lower Urinary Tract Symptom
  • Detrusor Overactivity
  • International Prostate Symptom Score

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
USD   44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions


  • American Urological Association (2013) Retrieved 21 Sept 2014. From

  • Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM, Papadouris D, Rholl KS, Smirniotopoulos JB, van Breda A (2014) Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 25(1):47–52.

    Google Scholar 

  • Djavan B, Kazzazi A, Bostanci Y (2012) Revival of thermotherapy for benign prostatic hyperplasia. Curr Opin Urol 22(1):16–21

    CrossRef  PubMed  Google Scholar 

  • Espinosa G (2013) Nutrition and benign prostatic hyperplasia. Curr Opin Urol 23(1):38–41

    PubMed  Google Scholar 

  • Gacci M, Carini M, Salvi M, Sebastianelli A et al. (2014) Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. Drugs Aging 31:425–439

    CrossRef  CAS  PubMed  Google Scholar 

  • Georg Muller AB (2014) Vaporization techniques for benign prostatic obstruction: Green Light all the way? Curr Opin Urol 24(1):42–48

    CrossRef  PubMed  Google Scholar 

  • Gilling AA (2013) Which laser works best for benign prostatic hyperplasia? Curr Urol Rep 141:614–619

    Google Scholar 

  • Ishio J, Nakahira J, Sawai T, Inamoto T, Fujiwara A, Minami T (2015) Change in serum sodium level predicts clinical manifestations of transurethral resection syndrome: a retrospective review. BMC Anesthesiol. doi:10.1186/s12871-015-0030-z

  • McConnell JD (1997) Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. In: Campbell’s urology, 7th edn, vol. 2. W. B. Saunders

    Google Scholar 

  • McConnell JD (1998) Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. In: John D. McConnell M, Patrick C. Walsh MA (ed) Campbell’s urology, 7th edn, vol. 2. W.B. Saunders Company, Philadelphia, pp 1429–1452

    Google Scholar 

  • McNicholas TA, Kirby RS, Lepor H (2012) Evaluation and nonsurgical management of benign prostatic hyperplasia. Campbell-Walsh Urology. Elsevier Saunders, Philadelphia, pp 2611–2654

    Google Scholar 

  • Paolone DR (2010) Benign prostatic hyperplasia. Clin Geriatr Med 26:223–239

    CrossRef  PubMed  Google Scholar 

  • Parsons OA (2014) Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms. Curr Opin Urol 24(1):10–14

    CrossRef  PubMed  Google Scholar 

  • Prescribing information (copyright 2003–2014) Eli Lilly and Company pp 1–29. Marketed by Lilly USA LLC Indianapolis in 46285, USA.

  • Presti JC (2004) Neoplasms of the prostate gland. In: McAninch EA, editor. Smith’s general urology. 16th ed. Lange Medical Books/McGraw-Hill, New York, pp 367–385

    Google Scholar 

  • Resnick MI (2003) Benign prostatic hyperplasia. In: Resnick MI (ed) Urology secrets, 3rd edn. Hanley & Belfus, Inc, Philadelphia, pp 98–101

    Google Scholar 

  • Russo A, La Croce G, Capogross P, Ventimislia E et al. (2014) Latest pharmacotherapy options for benign prostatic hyperplasia. Expert Opin Pharmacother 1–10

    Google Scholar 

  • Silva J, Silva CM, Cruz F (2014) Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Curr Opin Urol 24(1):21–28

    CrossRef  PubMed  Google Scholar 

  • Turini GA III (2009) Update on minimally invasive therapies for benign prostatic hyperplasia. Med Health/Rhode Island 92(10):336–338

    Google Scholar 

  • Wein AJ, Kavoussi LR, Campbell ME (2012) Benign prostatic hyperplasia. In: Roehrborn G.Claus, Campbell-Walsh Urology. Elsevier Saunders, Philadelphia, pp 2570–2610

    Google Scholar 

  • Wieder JA (2010) Benign prostatic hyperplasia, prostate specific antigen (PSA). In: Wieder JA, Pocket guide to urology, 4th edn. J. Wieder Medical in association with Griffith Publishing, Caldwell. pp 172–183, 160–163

    Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Gail M. Briolat ANCP-BC .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Briolat, G.M. (2016). Benign Prostatic Hyperplasia. In: Lajiness, M., Quallich, S. (eds) The Nurse Practitioner in Urology. Springer, Cham.

Download citation

  • DOI:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-28741-6

  • Online ISBN: 978-3-319-28743-0

  • eBook Packages: MedicineMedicine (R0)